Harnessing the power of the BioXp™ system
Given the COVID-19 global healthcare emergency, accelerating the pace of innovation and developing tools to combat the spread of COVID-19 is paramount. The scientific community is operating at its creative best to identify and advance solutions for prevention, detection, and treatment. The BioXp™ system is the ideal platform to enable researchers around the world to rapidly synthesize SARS-CoV-2 genome parts, making them readily available for developing vaccines, diagnostics, and therapeutics.
In this application note, we describe the on-demand production of the entire genome of SARS-CoV-2. Genome parts were designed and synthesized using the BioXp™ system. We also describe the joining of these parts to assemble the full-length genome of SARS-CoV-2 as a bacterial artificial chromosome (BAC) in E. coli. Given the number of genome variants of SARS-CoV-2 that have been identified thus far, it may become imperative to incorporate them into the vaccine, therapeutic, and diagnostic development pipelines quickly. The BioXp™ system accelerates this pipeline by enabling rapid synthesis of up to 32 individual variant genome parts in a single overnight run of the instrument.
By clicking submit, you agree that Telesis Bio may use this information to contact you about our programs, products, or services. You may opt out at any time.